Ocular Therapeutix stock
OCULNASDAQOcular Therapeutix, Inc., HealthcareISIN US67576A1007
34Score 34 out of 100, Weak
Price and trend
40 / 100
Price history
−45% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 30% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 61% below its 52-week high. Largest decline in 12 years: 95% (March 2015 to November 2023).
Chart figures for advanced users
- SMA 50$8.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.92
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.28
- The lowest closing price of the last twelve months.
- Resistance$16.11
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ocular Therapeutix, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.38B, is number 157 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $51.82M (down 18.7% year on year) and a loss of $265.94M.
- For fiscal 2026, analysts expect on average revenue of $52.77M (up 1.8%) and adjusted earnings per share of −$1.50.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 633 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $530.61M, financial debt $80.01M.Stability 53
Weaknesses
- DilutionShare count up 208% since 2020.Capital allocation 18
- Loss-makingLoss of $326.81M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$267.04M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 35 to 34.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 9.7% on the twelve months before. Revenue has grown strongly since 2014, at around 47% per year. From 2014 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 87%, operating −521%, net −513%. Last 12 months: net −100%. From 2014 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 9 Nov 2026EPS reported −$0.42 (expected −$0.36)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.500.0%
- Revenue
- $52.77M0.0%
- Earnings per share
- −$1.480.0%
- Revenue
- $100.36M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −0.6%Timeline accelerated: SOL-R top line data now guided to the first quarter of 2027; cash is expected to provide runway into 2028.
“We ended the first quarter with approximately $667 million in cash, which we expect to provide us runway into 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $1.16M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Saroj NamrataSale
5 Nov 2026, Chief Business Officer
- Shares
- 35,370
- Price
- $6.55
- Value
- $231,674
- Anderman ToddSale
8 Oct 2026, Chief Legal Officer
- Shares
- 11,984
- Price
- $7.29
- Value
- $87,363
- Kaiser PeterSale
2 Oct 2026, Chief Development Officer
- Shares
- 9,990
- Price
- $7.05
- Value
- $70,430
Show 11 more
- Heier Jeffrey S.Sale
2 Oct 2026, Chief Scientific Officer
- Shares
- 10,869
- Price
- $7.05
- Value
- $76,626
- Notman DonaldSale
31 Aug 2026, Chief Operating Officer
- Shares
- 1,099
- Price
- $10.24
- Value
- $11,254
- Kaiser PeterSale
24 Aug 2026, Chief Development Officer
- Shares
- 3,035
- Price
- $10.77
- Value
- $32,687
- Nayak SanjaySale
24 Aug 2026, Chief Strategy Officer
- Shares
- 1,897
- Price
- $10.78
- Value
- $20,450
- Heier Jeffrey S.Sale
24 Aug 2026, Chief Scientific Officer
- Shares
- 3,296
- Price
- $10.78
- Value
- $35,531
- Dugel PravinSale
24 Aug 2026, See Remarks
- Shares
- 21,649
- Price
- $10.77
- Value
- $233,160
- Waheed NadiaSale
3 Jun 2026, Chief Medical Officer
- Shares
- 14,828
- Price
- $8.27
- Value
- $122,628
- Dugel PravinSale
26 May 2026, See Remarks
- Shares
- 21,156
- Price
- $8.20
- Value
- $173,479
- Kaiser PeterSale
26 May 2026, Chief Development Officer
- Shares
- 2,967
- Price
- $8.20
- Value
- $24,329
- Heier Jeffrey S.Sale
26 May 2026, Chief Scientific Officer
- Shares
- 3,018
- Price
- $8.20
- Value
- $24,748
- Nayak SanjaySale
26 May 2026, Chief Strategy Officer
- Shares
- 1,858
- Price
- $8.20
- Value
- $15,236
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ocular Therapeutix
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Nuvation BioNUVB $1.43B29
- AnaptysBioANAB $1.43B60
- Alto NeuroscienceANRO $1.42B41
- Ascentage Pharma Group InternationalAAPG $1.4B37
- LB PharmaceuticalsLBRX $1.37B49
- Mineralys TherapeuticsMLYS $1.37B29
- Damora TherapeuticsDMRA $1.36B38
- Tyra BiosciencesTYRA $1.36B36
ETFs that hold Ocular Therapeutix
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 19 Dec 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.